Amylyx Pharmaceuticals Inc stock is traded at $27.62, with a volume of 1,767,998. It is down -6.05% in the last 24 hours and down -0.58% over the past month. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Previous Close:
$29.40
Open:
$30.23
24h Volume:
1,767,998
Relative Volume:
1.43
Market Cap:
$3.47B
Revenue:
-$665.00K
Net Income/Loss:
-$150.11M
P/E Ratio:
-
EPS:
-$1.51
Net Cash Flow:
-$124.53M
1W Performance:
-3.70%
1M Performance:
-0.58%
6M Performance:
+68.11%
1Y Performance:
+108.61%
1-Day Range:
$27.48$30.23
1-Week Range:
$27.48$30.68
52-Week Range:
$10.83$41.14
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals IncSector
HealthcarePhone
617-682-0917Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS